# Contact AgeDefy Peptides — Editorial Desk

> Reach the AgeDefy Peptides editorial desk for citation corrections, research updates, or correspondence about our NAD+ and MOTS-c longevity-research digest.

Correspondence about citations, corrections, and research updates — the things a literature digest most wants to hear.

## Editorial correspondence

AgeDefy Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory detail that has gone out of date, or a peer-reviewed study on NAD+, MOTS-c, or related longevity-research molecules that belongs on the [references page](/references). Corrections that improve accuracy are the most useful messages we receive, and they are read seriously.

The most actionable notes specify three things: the page they concern, the passage in question, and the supporting citation — a DOI or PubMed identifier where available.

**Editorial mailbox:** editors@agedefypeptides.com

## What this desk cannot do

AgeDefy Peptides is a literature digest, not a clinic or a vendor. Correspondence on the following falls outside what this site can address:

- Advice on, or commentary about, human use of any compound discussed here.
- Dosing, scheduling, or route recommendations for any individual.
- Diagnosis of any medical condition.
- Assistance sourcing, purchasing, or evaluating any research compound or supplement.
- Guidance for athletes on anti-doping matters (MOTS-c is treated as prohibited; any athlete should consult their sport's governing body).

Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction.

---

An independent literature digest tracing the published science of cellular aging — study by study, mechanism by mechanism, never a product and never advice.